|
Secondary malignant neoplasm of colon and/or rectum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 rs776746 A>G polymorphisms have a prognostic contribution toward FOLFIRI regimen in mCRC.
|
25934339 |
2015 |
|
Leukopenia
|
0.060 |
Biomarker
|
disease |
BEFREE |
CYP3A5*3/*1 patients showed a significantly higher risk of developing leukopenia (P < .001; Pearson's χ(2) test) and neutropenia (P < .001; Pearson's χ(2) test) than CYP3A5*3*3 patients.
|
26179145 |
2016 |
|
Neutropenia
|
0.040 |
Biomarker
|
disease |
BEFREE |
CYP3A5*3/*1 patients showed a significantly higher risk of developing leukopenia (P < .001; Pearson's χ(2) test) and neutropenia (P < .001; Pearson's χ(2) test) than CYP3A5*3*3 patients.
|
26179145 |
2016 |
|
Peripheral Neuropathy
|
0.030 |
Biomarker
|
group |
BEFREE |
CYP3A5 nonexpressor status has been associated with vincristine-induced peripheral neuropathy.
|
26565076 |
2016 |
|
Peripheral Nervous System Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
CYP3A5 nonexpressor status has been associated with vincristine-induced peripheral neuropathy.
|
26565076 |
2016 |
|
Kidney Failure, Chronic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
|
26773964 |
2015 |
|
Chronic kidney disease stage 5
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
|
26773964 |
2015 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
|
26855150 |
2016 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP3A5 also contributes to acquired drug resistance in QM-PDA and classical PDAC, and it is highly expressed in several additional malignancies.
|
26855150 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYP3A5 also contributes to acquired drug resistance in QM-PDA and classical PDAC, and it is highly expressed in several additional malignancies.
|
26855150 |
2016 |
|
Sleep Apnea, Central
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.
|
29113387 |
2017 |
|
Cockayne Syndrome, Type I
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.
|
29113387 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
|
29115708 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
|
29115708 |
2018 |
|
Acute lymphocytic leukemia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
Adult Acute Lymphocytic Leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
|
31588878 |
2019 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Aryl hydrocarbon hydroxylase activity in lymphoblasts from normal Finnish adults and from patients with pulmonary carcinomas and other types of malignancy has been studied by a modification of previously used techniques.
|
437913 |
1979 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aryl hydrocarbon hydroxylase activity in lymphoblasts from normal Finnish adults and from patients with pulmonary carcinomas and other types of malignancy has been studied by a modification of previously used techniques.
|
437913 |
1979 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aryl hydrocarbon hydroxylase activity in lymphoblasts from normal Finnish adults and from patients with pulmonary carcinomas and other types of malignancy has been studied by a modification of previously used techniques.
|
437913 |
1979 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aryl hydrocarbon hydroxylase activity in pulmonary alveolar macrophages and lymphocytes from lung cancer and noncancer patients: a correlation with family histories of cancer.
|
540021 |
1979 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aryl hydrocarbon hydroxylase activity in pulmonary alveolar macrophages and lymphocytes from lung cancer and noncancer patients: a correlation with family histories of cancer.
|
540021 |
1979 |
|
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aryl hydrocarbon hydroxylase activity in pulmonary alveolar macrophages and lymphocytes from lung cancer and noncancer patients: a correlation with family histories of cancer.
|
540021 |
1979 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aryl hydrocarbon hydroxylase activity in pulmonary alveolar macrophages and lymphocytes from lung cancer and noncancer patients: a correlation with family histories of cancer.
|
540021 |
1979 |